Tech Company Inital Public Offerings
Catabasis Pharmaceuticals IPO
On 6/25/2015, Catabasis Pharmaceuticals went public.
Transaction Overview
Company Name
Announced On
6/25/2015
Transaction Type
IPO
Amount
$60,000,000
Proceeds Purpose
As of March 31, 2015, we had cash and cash equivalents of approximately $24.3 million. We currently estimate that we will use the net proceeds from this offering, together with our cash and cash equivalents, as follows: approximately $30.0 million for the clinical development of CAT-1004; approximately $15.0 million for the clinical development of CAT-2054; and the remainder for other product candidates, working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 Kendall Sq. B14202
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
At Catabasis (NASDAQ: CATB) we are dedicated to the discovery and development of innovative, effective and safe medicines to treat inflammatory and metabolic diseases. We have assembled a team of highly motivated and experienced scientists who are committed to improving the lives of patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jill Milne
Chief Financial Officer
Ian Sanderson
Chief Medical Officer
Joanne Donovan
Browse more venture capital transactions:
Prev: 6/25/2015: Brazen venture capital transaction
Next: 6/25/2015: Andela venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC transactions reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs